Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer
- PMID: 18373987
- DOI: 10.1016/j.apmr.2007.09.042
Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer
Abstract
Treatment disparities for disabled Medicare beneficiaries with stage I non-small cell lung cancer.
Objective: To compare initial treatment and survival of nonelderly adults with and without disabilities newly diagnosed with non-small cell lung cancer.
Design: Retrospective analyses; population-based cohorts.
Setting: Eleven Surveillance, Epidemiology, and End Results cancer registries.
Participants: Persons with disability Medicare entitlement (n=1016) and nondisabled persons (n=8425) ages 21 to 64 years when diagnosed with stage I, pathologically confirmed, first primary non-small cell lung cancer between January 1, 1988, and December 31, 1999.
Interventions: Not applicable.
Main outcome measures: Initial cancer treatments (surgery, radiotherapy), survival (through December 31, 2001). Multivariable logistic regression and Cox proportional hazards regression estimated adjusted associations of disability status with treatments and survival.
Results: Persons with disabilities were much more likely to be male, non-Hispanic black, and not currently married. Although 82.2% of nondisabled persons had surgery, 68.5% of disabled persons received operations. Adjusted relative risks (RRs) of receiving surgery were especially low for persons with respiratory disabilities (adjusted RR=.76; 95% confidence interval [CI], .67-.85), nervous system conditions (adjusted RR=.86; 95% CI, .76-.98), and mental health and/or mental retardation disorders (adjusted RR=.92; 95% CI, .86-.99). Persons with disabilities had significantly higher cancer-specific mortality rates (hazard ratio [HR]=1.37; 95% CI, 1.24-1.51) than persons without disabilities. Observed differences in cancer mortality persisted after adjusting for demographic and tumor characteristics (adjusted relative HR=1.23; 95% CI, 1.10-1.39). Further adjustment for surgery use eliminated statistically significant differences in cancer mortality between persons with and without disabilities across disabling conditions.
Conclusions: Persons with disabilities were much less likely than nondisabled Medicare beneficiaries to receive surgery; statistically significant cancer-specific mortality differences disappeared after accounting for these treatment differences. Future research must explore reasons for these findings and whether survival of disabled Medicare beneficiaries with early-stage, non-small cell lung cancer could improve if surgical treatment disparities were eliminated.
Similar articles
-
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.J Clin Oncol. 2004 Dec 15;22(24):4971-8. doi: 10.1200/JCO.2004.05.031. J Clin Oncol. 2004. PMID: 15611512
-
Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival.J Thorac Cardiovasc Surg. 2012 Jun;143(6):1307-13. doi: 10.1016/j.jtcvs.2012.01.078. Epub 2012 Feb 22. J Thorac Cardiovasc Surg. 2012. PMID: 22361247
-
Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.Res Rep Health Eff Inst. 2009 Mar;(139):5-71; discussion 73-89. Res Rep Health Eff Inst. 2009. PMID: 19554969
-
Arterial invasion predicts early mortality in stage I non-small cell lung cancer.Ann Thorac Surg. 2004 Nov;78(5):1748-53. doi: 10.1016/j.athoracsur.2004.04.061. Ann Thorac Surg. 2004. PMID: 15511466 Review.
-
What is the optimal treatment of stage IIIA-N2 non-small-cell lung cancer after EORTC 08941?Expert Rev Anticancer Ther. 2008 Feb;8(2):199-206. doi: 10.1586/14737140.8.2.199. Expert Rev Anticancer Ther. 2008. PMID: 18279061 Review.
Cited by
-
Do people with disabilities experience disparities in cancer care? A systematic review.PLoS One. 2023 Dec 13;18(12):e0285146. doi: 10.1371/journal.pone.0285146. eCollection 2023. PLoS One. 2023. PMID: 38091337 Free PMC article.
-
Assessing cancer in people with profound and multiple disabilities.BMC Cancer. 2023 Aug 25;23(1):798. doi: 10.1186/s12885-023-11313-3. BMC Cancer. 2023. PMID: 37626285 Free PMC article.
-
Impact of functional disability on health-care use and medical costs among cancer survivors.JNCI Cancer Spectr. 2023 Aug 31;7(5):pkad059. doi: 10.1093/jncics/pkad059. JNCI Cancer Spectr. 2023. PMID: 37584678 Free PMC article.
-
Research Priorities for Interventions to Address Health Disparities in Lung Nodule Management: An Official American Thoracic Society Research Statement.Am J Respir Crit Care Med. 2023 Mar 15;207(6):e31-e46. doi: 10.1164/rccm.202212-2216ST. Am J Respir Crit Care Med. 2023. PMID: 36920066 Free PMC article.
-
Rural-Urban Disparities in Receipt of Surgery for Potentially Resectable Non-Small Cell Lung Cancer.J Surg Res. 2023 Mar;283:1053-1063. doi: 10.1016/j.jss.2022.10.097. Epub 2022 Dec 14. J Surg Res. 2023. PMID: 36914996 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical